Abstract
We report a case of delayed enhancement of myocardial FDG uptake in NIDDM patient after oral glucose loading. A 65-year-old man who had a past history of NIDDM received FDG-PET examination during fasting and glucose loading. In neither condition, was an accumulation of FDG in the myocardium, and myocardial blood flow was normal. An oral glucose tolerance test (OGTT) was performed to find the best time for FDG injection and 3 hours after loading, the serum insulin concentration was increased significantly. When the interval between glucose loading and the injection of FDG was set at 3 hours, enhancement of myocardial FDG uptake was demonstrated. To know the best time for the FDG injection in advance is thought to be important in obtaining better image quality and interpreting the myocardial viability when FDG-PET examination during glucose loading is performed in NIDDM patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Prellwitz J, Vatsta M, Sunderland J, Shiue C-Y, Gupta N, Frick M. Investigation of factors influencing FDG myocardial image quality [Abstract].J Nucl Med 32: 1039, 1991.
vom Dahl J, Hicks R, Lee K, Eitzman D, Alaouar Z, Schwaiger M. PET myocardial viability studies in patients with diabetes mellitus [Abstract].J Am Coll Cardiol 17: 121A, 1991.
Ohtake T, Yokoyama I, Watanabe T, Momose T, Serizawa T, Nishikawa J, et al. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET.J Nucl Med 36: 456–463, 1995.
Stanley CW, Hall JL, Smith KR, Cartee GD, Hacker TA, Wisneski JA. Myocardial glucose transporter and glycolytic metabolism during ischemia in hyperglycemic diabetic swine.Metabolism 43: 61–69, 1994.
Sun D, Nguyen N, DeGrado TR, Schwaiger M, Brosius FC III. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes.Circulation 89: 793–798, 1994.
Hicks R, vom Dahl J, Lee K, Herman W, Kalff V, Schwaiger M. Insulin-glucose clamp for standardization of metabolic conditions during F-18 fluorodeoxyglucose PET imaging.J Am Coll Cardiol 17: 381A, 1991.
Knuuti MJ, Nuutila P, Ruotsalainen U, Saraste M, Harkonen R, Ahonen A, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography.J Nucl Med 33: 1255–1262, 1992.
vom Dahl J, Herman WH, Hicks RJ, Ortiz-Alonso FJ, Lee KS, Allman KC, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic PET.Circulation 88: 395–404, 1993.
Voipio-Pulkki LM, Nuutila P, Knuuti MJ, Haaparanta M, Teras M, Wegelius-U, et al. Heart and skeletal muscle glucose disposal in type 2 diabetic patient as determined by positron emission tomography.J Nucl Med 34: 2064–2067, 1993.
Garvey WT. Glucose transport and NIDDM.Diabetes Care 15: 396–417, 1992.
Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease.Diabetes 37: 1595–1607, 1988.
Defronzo RA. Lilly Lecture 1988: the triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37: 667–687, 1988.
Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes.Diabetes 34: 222–234, 1985.
Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG. Insulin treatment reserves the insulin resistance of type II diabetes mellitus.Diabetes Care 5: 353–363, 1982.
Ginsberg H, Rayfield EJ. Effect of insulin therapy on insulin resistance in type II diabetic subjects: evidence for heterogeneity.Diabetes 30: 739–745, 1981.
Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley JE, Unger R. Insulin therapy in obese NIDDM induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal.Diabetes 33: 634–642, 1984.
Henry RR, Wallace P, Olefsky JM. Effect of weight loss on mechanism of hyperglycemia in obese non-insulin dependent diabetes mellitus.Diabetes 35: 990–998, 1986.
Zawadzki JK, Bogardus C, Foley JE. Insulin action in obese non-insulin dependent diabetes and in their isolated adipocytes before and after weight loss.Diabetes 36: 227–236, 1987.
Greenfield MS, Doberne L, Rosenthal M, Schulz B, Widstrom A, Reaven GM. Effects of sulfonylurea treatment onin vivo secretion and action in patients with non-insulindependent diabetes mellitus.Diabetes 31: 307–312, 1982.
Kolterman OG, Gray RS, Shapiro G, Scalett JA, Griffin J, Olesky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects.Diabetes 33: 346–354, 1984.
Knuuti MJ, Yki-Jarvinen H, Voipio-Pulkki LM, Maki M, Ruotosalainen U, Harkonen R, et al. Enhancement of myocardial [Fluorine-18]Fluorodeoxyglucose uptake by a nicotinic acid derivative.J Nucl Med 35: 989–998, 1994.
Monti LD, Lucignani G, Landoni C, Moresco RM, Piatti P, Stefani I, et al. Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients.Diabetes 44: 537–542, 1995.
Stone CK, Holden JE, Stanley W, Perlman SB. Effect of nicotinic acid on exogenous myocardial glucose utilization.J Nucl Med 36: 996–1002, 1995.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsuchida, T., Yonekura, Y., Wada, Y. et al. Delayed enhancement of myocardial FDG uptake on glucose loading FDG-PET in NIDDM patient. Ann Nucl Med 11, 331–334 (1997). https://doi.org/10.1007/BF03165302
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03165302